Prolia Treatment - Case Study 2 | Osteoporosis | Amgen

Is this your next Prolia® patient?

70-year-old woman with diagnosed osteoporosis and reflux disease.
70-year-old woman with diagnosed osteoporosis and reflux disease
  • No known history of fracture
  • Recent DXA scans revealed bone mineral density T-score –3.0 at the spine and –2.5 at the hip
  • Diet is limited due to reflux disease; currently treated with pantoprazole (40 mg)

Criteria: Why should she receive Prolia®?

  • The risk of fracture is more than three times greater for women aged >70 years compared with women aged 50 years1
  • Recent diagnosis of osteoporosis; bone mineral density T-score -3.0 at the spine and -2.5 at the hip
  • Patients with pre-existing gastrointestinal disorders should preferably not be treated with oral bisphosphonates2,3*
  • Prolia® significantly reduces fracture risk over 3 years of treatment at key sites compared with placebo4
  • 10 years of Prolia® is associated with a favourable benefit/risk profile:5
    • Continuous increases in bone mineral density
    • Well tolerated
  • Patients prefer the convenient twice-yearly subcutaneous administration of Prolia® injections over oral bisphosphonates6–8
  • Prolia® is not associated with upper gastrointestinal complaints that are common with oral bisphosphonate use2,3,9*
Back
References:
*Adverse gastrointestinal drug reactions with bisphosphonates include: irritation of the esophagus, difficulty swallowing, pain on swallowing, and heartburn. Patients with pre-existing upper gastrointestinal disorders, such as esophageal stricture, achalasia, or poorly controlled gastroesophageal reflux disease, should preferably not be treated with oral bisphosphonates.2
Abdominal discomfort and constipation have been reported in patients with osteoporosis receiving Prolia®.9
DXA: dual x-ray absorptiometry.
  1. Kanis JA, et al. Osteoporos Int. 2001;12:989–95.
  2. Rizzoli R, et al. Osteoporos Int. 2014;25:2507–29.
  3. Fosavance® (alendronate) Summary of Product Characteristics.
  4. Cummings SR, et al. N Engl J Med. 2009;361:756–65.
  5. Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.
  6. Freemantle N, et al. Osteoporos Int. 2012;23:317–26.
  7. Palacios S, et al. J Clin Endocrinol Metab. 2015;100:E487–92.
  8. Kendler DL, et al. Osteoporos Int. 2011;22:1725–35.
  9. Prolia® (denosumab) Summary of Product Characateristics. Amgen.

SMPC

The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public